Earningsreport

Q3/2025 9/30/2025 EPS -0.300 ZacksConsensus -0.040 ActVsEst (0.260) - Miss

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com